Guardant Health (GH) said Wednesday it introduced a full suite of immunohistochemistry, or IHC, testing for key biomarkers in all solid tumors, such as lung, breast, gastric and ovarian cancers.
The company said IHC testing detects tumor biomarkers that can be used to determine a tumor's characteristics and identify the most suitable targeted cancer treatment.
The new tests are now available in addition to the Guardant360 Tissue multiomic tumor profiling test, the company said.
Shares of Guardant Health were down more than 4% in recent trading.
Price: 38.19, Change: -1.78, Percent Change: -4.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。